| Gene | Gene Full Name | DSI g | DPI g | pLI | Disease | Type | Score gda | EL gda | EI gda | N. PMIDs | N. SNPs gda | First Ref. | Last Ref. | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
sodium voltage-gated channel alpha subunit 5 | 0.513 | 0.654 | 0.91 |
|
disease | 1.000 | definitive | 0.984 | 1 | 1 | 1995 | 2020 | ||||||||
|
angiotensin I converting enzyme | 0.328 | 0.923 | 1.0E-37 |
|
disease | 0.900 | strong | 0.915 | 1 | 1 | 1998 | 2020 | ||||||||
|
glucokinase | 0.523 | 0.808 | 0.63 |
|
disease | 0.900 | strong | 0.953 | 1 | 1 | 1992 | 2020 | ||||||||
|
APC regulator of WNT signaling pathway | 0.373 | 0.962 | 1.00 |
|
group | 0.900 | None | 0.982 | 1 | 1 | 1990 | 2019 | ||||||||
|
interferon regulatory factor 6 | 0.486 | 0.769 | 1.00 |
|
disease | 0.900 | None | 0.923 | 1 | 1 | 2003 | 2019 | ||||||||
|
BRCA2 DNA repair associated | 0.379 | 0.846 | 2.4E-25 |
|
disease | 0.900 | None | 0.947 | 1 | 2 | 1994 | 2020 | ||||||||
|
major histocompatibility complex, class II, DQ beta 1 | 0.407 | 0.885 | 8.9E-03 |
|
disease | 0.800 | limited | 0.956 | 1 | 1 | 1996 | 2019 | ||||||||
|
APC regulator of WNT signaling pathway | 0.373 | 0.962 | 1.00 |
|
disease | 0.800 | strong | 0.972 | 1 | 1 | 1990 | 2020 | ||||||||
|
sodium voltage-gated channel alpha subunit 10 | 0.566 | 0.692 | 9.9E-38 |
|
disease | 0.800 | disputed | 0.929 | 1 | 1 | 1998 | 2019 | ||||||||
|
synuclein alpha | 0.427 | 0.885 | 0.88 |
|
disease | 0.800 | None | 0.973 | 1 | 1 | 1998 | 2020 | ||||||||
|
tumor protein p63 | 0.362 | 0.769 | 1.00 |
|
disease | 0.720 | strong | 1.000 | 1 | 1 | 2006 | 2017 | ||||||||
|
ADAM metallopeptidase domain 10 | 0.489 | 0.846 | 1.00 |
|
disease | 0.700 | None | 0.986 | 1 | 1 | 2000 | 2019 | ||||||||
|
aldehyde dehydrogenase 2 family member | 0.457 | 0.885 | 3.4E-10 |
|
disease | 0.700 | None | 1.000 | 1 | 1 | 1991 | 2019 | ||||||||
|
filaggrin | 0.525 | 0.846 | 2.9E-04 |
|
disease | 0.700 | moderate | 0.961 | 1 | 1 | 2005 | 2020 | ||||||||
|
SH2B adaptor protein 1 | 0.566 | 0.731 | 0.97 |
|
disease | 0.700 | moderate | 0.906 | 1 | 1 | 2009 | 2020 | ||||||||
|
glutamate ionotropic receptor NMDA type subunit 2B | 0.510 | 0.692 | 1.00 |
|
disease | 0.700 | None | 0.972 | 1 | 1 | 2000 | 2020 | ||||||||
|
glycogen synthase kinase 3 beta | 0.430 | 0.846 | 0.96 |
|
disease | 0.700 | None | 0.982 | 1 | 1 | 2000 | 2020 | ||||||||
|
T-box transcription factor 21 | 0.541 | 0.808 | 1.00 |
|
disease | 0.700 | None | 0.944 | 1 | 1 | 2002 | 2019 | ||||||||
|
major histocompatibility complex, class I, B | 0.379 | 0.885 | 3.9E-05 |
|
disease | 0.700 | None | 0.987 | 1 | 1 | 2004 | 2020 | ||||||||
|
major histocompatibility complex, class II, DQ beta 1 | 0.407 | 0.885 | 8.9E-03 |
|
disease | 0.700 | None | 0.929 | 1 | 1 | 2003 | 2014 | ||||||||
|
major histocompatibility complex, class II, DR beta 1 | 0.333 | 0.923 | 1.1E-03 |
|
disease | 0.700 | None | 0.880 | 1 | 1 | 1994 | 2019 | ||||||||
|
major histocompatibility complex, class II, DR beta 1 | 0.333 | 0.923 | 1.1E-03 |
|
disease | 0.700 | None | 0.870 | 1 | 2 | 1993 | 2013 | ||||||||
|
apolipoprotein E | 0.338 | 0.962 | 1.9E-03 |
|
disease | 0.700 | None | 0.966 | 1 | 1 | 1983 | 2019 | ||||||||
|
apolipoprotein E | 0.338 | 0.962 | 1.9E-03 |
|
group | 0.700 | None | 0.897 | 1 | 1 | 1994 | 2019 | ||||||||
|
interleukin 5 | 0.437 | 0.846 | 5.7E-03 |
|
disease | 0.700 | None | 0.973 | 1 | 1 | 1991 | 2020 |